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S U M M A R Y
Objectives: Effective treatment with direct-acting antiviral drugs against hepatitis C virus (HCV) is a
medical need in cirrhotic HIV–HCV co-infected patients.
Methods: This study investigated the plasma levels of daclatasvir (DCV) and ribavirin (RBV) in HIV–HCV
co-infected subjects treated with DCV, sofosbuvir, and RBV. Drug concentrations were quantiﬁed using
validated high-performance liquid chromatography methods with ultraviolet detection. The HCV non-
structural protein 5A and non-structural protein 5B coding regions were analyzed by population-based
sequencing.
Results: DCV was dosed at week 4 and at week 8 of treatment, and RBV at week 8. One patient had the
lowest DCV level, corresponding to 32.7% of the overall median value of the other patients at week 4 and
about 40% at week 8. The Y93H variant was detected in this subject at weeks 8, 16, and 20 of treatment,
but not before treatment or at day 2, and the patient experienced virological failure. Another subject with
the Y93H variant at baseline and appropriate DCV levels had HCV RNA <12 IU/ml at week 12 and
undetectable at week 16.
Conclusions: Sub-optimal DCV drug levels allow the selection of resistance-associated variants and fail
to contribute to antiviral activity. No deﬁnite reason for the low DCV level was found. Quantifying the
drug is suggested in difﬁcult-to-treat patients.
 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Patients with HIV infection and hepatitis C virus (HCV)-induced
cirrhosis are at high risk of liver failure-related morbidity and
mortality; thus, effective anti-HCV treatment represents a medical
need.1 The cases of eight HIV-positive patients on highly active
antiretroviral therapy (HAART) with HCV cirrhosis, all naı¨ve to
direct-acting antivirals for HCV (DAA) and treated with daclatasvir
(DCV), sofosbuvir (SOF), and ribavirin (RBV), are reported herein.* Corresponding author. Tel.: +39 0498272344; fax: +39 0498272355.
E-mail address: saverio.parisi@unipd.it (S.G. Parisi).
c Saverio G. Parisi and Arianna Loregian contributed equally
d Anna Maria Cattelan and Giorgio Palu` contributed equally
http://dx.doi.org/10.1016/j.ijid.2016.06.020
1201-9712/ 2016 The Author(s). Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).2. Patients and methods
Eight HIV-positive patients with Child–Pugh A HCV-related
(genotype 3) cirrhosis were treated with SOF (400 mg once daily),
DCV (60 mg once daily), and RBV (ﬁxed dose, 800 mg daily)
planned for 24 weeks. The successful HAART was modiﬁed in all
patients because of potential drug–drug interactions (Table 1). The
HCV non-structural protein 5A (NS5A) and non-structural protein
5B (NS5B) coding regions were analyzed by population-based
sequencing at baseline in six patients. DCV and RBV concentrations
were quantiﬁed using validated high-performance liquid chroma-
tography methods with ultraviolet detection (unpublished results)
in plasma collected before taking drugs (Ctrough).
2,3 The Ethics
Committee for Clinical Experimentation, Padova Province, was
notiﬁed of the study (27602/16).ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
Main characteristics of the HIV–HCV-infected patients at baseline
Patient Sex Age, years Previous
anti-HCV treatmenta
ART at baseline CD4+ cell count
(cells/mm3)
CD4+ cell
percentage
HIV RNA
(copies/ml)
NS5A NS5B
1 F 49 No TDF + FTC + RGV 320 18 UND 30S WT
2 M 52 Yes ATV 320 19 UND WT WT
3 M 64 No 3TC + RGV 380 40 UND WT WT
4 M 46 No ABC + 3TC + RGV 200 10 59 ND ND
5 M 57 No TDF + FTC + RPV 640 41 UND WT WT
6 M 50 Yes ABC + 3TC + RGV 430 35 UND WT WT
7 M 56 No TDF + FTC + RPV 1080 40 UND WT ND
8 M 52 No TDF + FTC + RPV 610 31 UND Y93H WT
ABC, abacavir; ART, antiretroviral therapy; ATV, atazanavir; F, female; FTC, emtricitabine; HCV, hepatitis C virus; M, male; ND, not determined; RGV, raltegravir; RPV,
rilpivirine; TDF, tenofovir; UND, undetectable (lower limit of quantiﬁcation 40 copies/ml); WT, wild type; 3TC, lamivudine.
a Interferon-based.
Table 2
HCV RNA kinetics during antiviral treatment, ribavirin dosing, and daclatasvir dosinga
Patient HCV RNAb
Baseline
HCV RNAb
Week 4
DCVc
Week 4
HCV RNAb
Week 8
and RAV
DCVc
Week 8 (a)
DCVc
Week 8 (b)
RBVc
Week 8
HCV RNAb
Week 12
HCV RNAb
Week 16
and RAV
HCV RNAb
Week 20
and RAV
HCV RNAb
Week 24
1 1746 UND 0.071 UND 0.124 0.095 4.01 UND UND UND UND
2 9 768 530 25 0.327 <12 0.415 0.469 1.012 UND UND UND UND
3 3 123 663 26 0.04 <12 0.088 0.092 1.847 <12 UND UND UND
4 2 170 547 248 0.152 47 0.113 0.114 1.509 <12 <12 UND UND
5 926 162 UND 0.153 UND 0.191 0.153 1.915 UND UND UND UND
6 4 746 034 213 0.061/0.056 231
Y93H/ND
0.046 0.05 1.74 331 3128
Y93H/ND
843
Y93H/ND
1986
7 155 869 20 0.185 <12 0.124 0.128 1.212 <12 UND UND UND
8 6 847 316 509 0.313 61 0.5 NA NA <12 UND N/AP N/AP
DCV, daclatasvir; HCV, hepatitis C virus; NA, not available; N/AP, not applicable (patient was still on therapy and did not achieve the speciﬁc week); ND, not detectable; RAV,
resistance-associated variant; RBV, ribavirin; UND, undetectable ( Lower limit of quantiﬁcation 12 IU/ml).
a Daclatasvir was tested twice in patient 6 at week 4 to conﬁrm plasma levels and it was tested twice in seven of the eight patients at week 8 (all results reported, (a) and
(b)). Patient 8 had no second daclatasvir determination at week 8 and no ribavirin dosing because no more samples were available. Resistance-associated variants at weeks 8,
16, and 20 are described as NS5A-related/NS5B-related.
b IU/ml.
c Ctrough, mg/ml.
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At the start of treatment with DAA, no naturally occurring
resistance-associated variant (RAV) was found in six subjects;
however the Y93H variant was found in one (patient 8). Six
patients had undetectable HCV RNA at week 24. Patient 8 was still
on therapy but with HCV RNA <12 IU/ml at week 12 and
undetectable at week 16, while patient 6 continued to have
detectable HCV RNA up to week 24. Patient 4 had consistently low
levels of plasma HIV RNA; all of the other patients had HIV RNA
fully suppressed throughout the study period.
DCV was dosed at week 4 and at week 8 of treatment, and RBV
at week 8. Patient 6 had a DCV level corresponding to 32.7% of the
overall median value of the other patients at week 4 and
corresponding to 37.1% and 41% in two repeat controls at week
8 (Table 2). The Y93H variant was identiﬁed in patient 6 at weeks 8,
16, and 20 of treatment, but not on day 2 of treatment. RBV levels
were within the normal range in all seven patients tested. All
patients had a 100% self-reported adherence to the treatment.
Patient 6 was questioned regarding his adherence, but he
conﬁrmed taking the drugs in a timely manner each day; in
keeping with this, his plasma HIV RNA was successfully
suppressed.
4. Discussion
The relationship between the DCV plasma level and the role of
the resistance mutant Y93H in determining the outcome of a
regimen containing DCV is reported here . Two therapy time pointswere selected to monitor the bioavailability of DCV in HIV–HCV-
infected patients (underexposure has been described previously
for RBV).4 The lowest DCV concentrations were observed in a
subject who experienced virological failure (patient 6). Also
patients 1 and 3 had low levels of DCV at week 4, but they
reached higher concentrations at week 8; their better outcomes
may relate to these different drug kinetics, or to the absence of 93H
quasispecies, or to the activity of the other two components of the
therapy. All patients had their successful HAART modiﬁed. These
data underline the strong need to treat all co-infected patients
regardless of the severity of liver ﬁbrosis in order to avoid the risk
of missing the chance to modify HAART in the case of resistance to
antiretrovirals .
For whatever reason, HCV RNA was always detectable in patient
6 and an NS5A resistance variant was identiﬁed at weeks 8, 16, and
20; NS5B sequences were not available due to the lower efﬁciency
of the NS5A sequencing procedure at low HCV RNA copies. The
patient’s RBV plasma concentration was in the therapeutic range.
Unfortunately, the patient’s SOF plasma level was not measured
and this is a limitation of the work. The failure to detect the Y93H
mutant at baseline in patient 6 underlines the utility of deep
sequencing to detect minor variants at baseline in difﬁcult-to-treat
subjects, such as HCV genotype 3 infected patients, to correctly
address the therapeutic strategy. The Y93H substitution is reported
to compromise the treatment with DCV,5 to confer high-level
resistance to DCV in genotype 3a patients, and to reduce the
binding afﬁnity of DCV to NS5A.6
Patient 8 achieved HCV RNA suppression despite the presence
of the Y93H mutation at baseline; of note, his DCV levels were
S.G. Parisi et al. / International Journal of Infectious Diseases 49 (2016) 151–153 153much higher than those found in patient 6. This result highlights
the importance of residual drug activity even in the presence of
RAVs and the importance of a therapeutic drug level to overcome
the role of RAVs in determining therapeutic failure when present as
either a minor or prevalent quasispecies. On the other hand, sub-
optimal drug levels allow the selection of RAVs and fail to
contribute to antiviral activity, as seen in patient 6. However, other
factors need to be taken into account, such as the baseline HCV
plasma level, body mass index, interleukin 28 (IL28) genotype, and
co-administered drug activity.7
The HAART regimen of patient 6 was compatible with the anti-
HCV therapy and no other drug with possible known interactions
was co-administered,8,9 so no deﬁnite reason for his low DCV level
was found. This suggests some difﬁculties in predicting DCV
therapeutic levels in HIV–HCV-infected cirrhotic patients on
HAART.
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